Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Phase 1 Clinical Trial Centre, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Diabetes Technol Ther. 2024 Jan;26(1):70-75. doi: 10.1089/dia.2023.0349. Epub 2023 Nov 27.
Continuous glucose monitoring (CGM) is proposed as an alternative for glycemic assessment in peritoneal dialysis, but volume overload and anemia may affect sensor accuracy. This is an exploratory analysis of a study of Guardian Connect™ with Guardian Sensor™ 3 in 30 participants with diabetes on continuous ambulatory peritoneal dialysis (CAPD) (age [mean ± standard deviation] 64.7 ± 5.6 years, 23 men, body mass index [BMI] 25.4 ± 3.9 kg/m, blood hemoglobin [Hb] 10.7 ± 1.3 g/dL). The mean absolute relative difference (MARD) was calculated between paired sensor and YSI 2300 STAT venous glucose readings ( = 941) during an 8-h in-clinic session with glucose challenge. Body composition was evaluated using bioimpedance. The overall MARD was 10.4% (95% confidence interval 9.6-11.7). There were no correlations between BMI, extracellular water, relative hydration index, and lean or fat mass with MARD. No correlations were observed between MARD and Hb ( = 0.016, > 0.05). In summary, this real-time CGM demonstrated good accuracy in CAPD with minimal influence from body composition and anemia.
连续血糖监测(CGM)被提议作为腹膜透析中血糖评估的替代方法,但容量超负荷和贫血可能会影响传感器的准确性。这是一项对使用 Guardian Connect™与 Guardian Sensor™ 3 对 30 名糖尿病持续非卧床腹膜透析(CAPD)患者(年龄[均值 ± 标准差]64.7 ± 5.6 岁,23 名男性,体重指数[BMI]25.4 ± 3.9 kg/m,血血红蛋白[Hb]10.7 ± 1.3 g/dL)进行的 Guardian Connect™研究的探索性分析。在 8 小时的门诊葡萄糖挑战期间,计算了配对传感器和 YSI 2300 STAT 静脉血糖读数之间的平均绝对相对差异(MARD)( = 941)。使用生物阻抗评估身体成分。总体 MARD 为 10.4%(95%置信区间 9.6-11.7)。BMI、细胞外液、相对水合指数、瘦体重和脂肪量与 MARD 之间均无相关性。MARD 与 Hb 之间也无相关性( = 0.016, > 0.05)。总之,这种实时 CGM 在 CAPD 中表现出良好的准确性,受身体成分和贫血的影响最小。